[{"id":"352829aa-e5d7-48c1-8c69-32ba5afa1e52","acronym":"CREATIVE","url":"https://clinicaltrials.gov/study/NCT04678102","created_at":"2021-01-19T20:46:06.378Z","updated_at":"2024-07-02T16:35:44.773Z","phase":"Phase 1","brief_title":"Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)","source_id_and_acronym":"NCT04678102 - CREATIVE","lead_sponsor":"Seoul National University Hospital","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • lasmotinib (PHI-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-06-26"},{"id":"ed49df08-4680-4945-9d90-96675cf4da59","acronym":"PHI-101-001","url":"https://clinicaltrials.gov/study/NCT04842370","created_at":"2021-04-13T14:30:43.505Z","updated_at":"2024-07-02T16:36:31.507Z","phase":"Phase 1a/1b","brief_title":"Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML","source_id_and_acronym":"NCT04842370 - PHI-101-001","lead_sponsor":"Seoul National University Hospital","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lasmotinib (PHI-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 05/21/2022","primary_completion_date":" 05/21/2022","study_txt":" Completion: 05/21/2022","study_completion_date":" 05/21/2022","last_update_posted":"2021-04-20"}]